JMP Securities Reiterates “Market Outperform” Rating for Inovio Pharmaceuticals (NASDAQ:INO)

JMP Securities reaffirmed their market outperform rating on shares of Inovio Pharmaceuticals (NASDAQ:INO) in a research note published on Friday,Benzinga reports. The firm currently has a $18.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on the stock. Oppenheimer decreased their price target on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday, November 18th. HC Wainwright decreased their price target on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating for the company in a research note on Monday, November 18th. Finally, Royal Bank of Canada cut their price objective on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Friday, November 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $12.80.

Inovio Pharmaceuticals Price Performance

INO stock opened at $1.98 on Friday. The company has a 50 day simple moving average of $3.42 and a 200 day simple moving average of $6.10. The stock has a market cap of $51.68 million, a price-to-earnings ratio of -0.95 and a beta of 0.84. Inovio Pharmaceuticals has a 1 year low of $1.74 and a 1 year high of $14.75.

Institutional Trading of Inovio Pharmaceuticals

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its holdings in Inovio Pharmaceuticals by 177.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 3,630 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at about $71,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Inovio Pharmaceuticals in the 2nd quarter valued at about $82,000. MetLife Investment Management LLC grew its stake in shares of Inovio Pharmaceuticals by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 8,546 shares during the period. Finally, Atom Investors LP acquired a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at about $103,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.